An independent data safety monitoring board (DSMB) recommended the early unblinding of the HIV Prevention Trials Network (HPTN) 084 study evaluating the safety and efficacy of investigational, long-acting injectable cabotegravir (CAB-LA; ViiV Healthcare) for HIV prevention in women because it demonstrated superiority to daily pre-exposure prophylaxis (PrEP).
After a prespecified interim analysis, the DSMB indicated that CAB, an investigational integrase inhibitor, met the